Literature DB >> 21941296

The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Gregory T Motz1, George Coukos.   

Abstract

Emerging evidence indicates that angiogenesis and immunosuppression frequently occur simultaneously in response to diverse stimuli. Here, we describe a fundamental biological programme that involves the activation of both angiogenesis and immunosuppressive responses, often through the same cell types or soluble factors. We suggest that the initiation of these responses is part of a physiological and homeostatic tissue repair programme, which can be co-opted in pathological states, notably by tumours. This view can help to devise new cancer therapies and may have implications for aseptic tissue injury, pathogen-mediated tissue destruction, chronic inflammation and even reproduction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941296     DOI: 10.1038/nri3064

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  143 in total

1.  Toll-like receptor 2 controls expansion and function of regulatory T cells.

Authors:  Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

2.  The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13.

Authors:  J Fukushi; M Ono; W Morikawa; Y Iwamoto; M Kuwano
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

3.  Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth.

Authors:  A Bagnato; D Salani; V Di Castro; J R Wu-Wong; R Tecce; M R Nicotra; A Venuti; P G Natali
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

4.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

5.  Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.

Authors:  Sachin Gupta; Kusum Joshi; J D Wig; Sunil K Arora
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

6.  Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice.

Authors:  Eugenio Stabile; Mary Susan Burnett; Craig Watkins; Timothy Kinnaird; Alessia Bachis; Andrea la Sala; Jonathan M Miller; Matie Shou; Stephen E Epstein; Shmuel Fuchs
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

7.  Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

Authors:  Jin-Young Shin; Il-Hee Yoon; Jung-Sik Kim; Bongi Kim; Chung-Gyu Park
Journal:  Cell Immunol       Date:  2009-02-26       Impact factor: 4.868

8.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 10.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Authors:  Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

View more
  173 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

Review 2.  Differential macrophage programming in the tumor microenvironment.

Authors:  Brian Ruffell; Nesrine I Affara; Lisa M Coussens
Journal:  Trends Immunol       Date:  2012-01-23       Impact factor: 16.687

3.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 4.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

5.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

Review 6.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

7.  Regeneration-associated cells improve recovery from myocardial infarction through enhanced vasculogenesis, anti-inflammation, and cardiomyogenesis.

Authors:  Amankeldi A Salybekov; Akira T Kawaguchi; Haruchika Masuda; Kosit Vorateera; Chisa Okada; Takayuki Asahara
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

8.  Lymphatic vessels regulate immune microenvironments in human and murine melanoma.

Authors:  Amanda W Lund; Marek Wagner; Manuel Fankhauser; Eli S Steinskog; Maria A Broggi; Stefani Spranger; Thomas F Gajewski; Kari Alitalo; Hans P Eikesdal; Helge Wiig; Melody A Swartz
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

Review 9.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

Review 10.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.